Evidence map›Paper›PMID 22129992›Full record

ReviewNature reviews. Drug discovery2011

Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets.

Joon-Il Jun, Lester F Lau

Abstract readReview
In one paragraph

Review in Nature reviews. Drug discovery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 383 papers.

0numbers the graph read from it
0cells of the map it votes in
383citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

383 citing papers in PubMed.

  1. Transcriptome screening and functional validation of FN1 in the regulation of granulosa cell proliferation in polycystic ovary syndrome.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Molecular Consequences ofInternational journal of molecular sciences · 2025
    Article
  18. Review
  19. Article
  20. Review

323 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Joon-Il JunDepartment of Biochemistry and Molecular Genetics, University of Illinois at Chicago, College of Medicine, 900 S. Ashland Avenue, Chicago, Illinois 60607, USA.
Lester F Lau

Funding

Regulation of TNF-alpha by Integrin-Mediated Matrix SignalingR01GM078492 · NIGMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI LAU, LESTER F · 2007 to 2018
$4.3M
The Matricellular Protein CCN1 in Wound HealingR01AR061791 · NIAMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI LAU, LESTER F · 2011 to 2021
$3.8M
Integrin-Matrix Interaction in Cardiovascular DevelopmentR01HL081390 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI LAU, LESTER F · 2007 to 2010
$1.6M
NHLBI NIH HHS HL81390NHLBI NIH HHS R01 HL081390NIAMS NIH HHS AR6179NIAMS NIH HHS R01 AR061791NIGMS NIH HHS GM78492NIGMS NIH HHS R01 GM078492
6 · The paper itself

Abstract

Members of the CCN family of matricellular proteins are crucial for embryonic development and have important roles in inflammation, wound healing and injury repair in adulthood. Deregulation of CCN protein expression or activities contributes to the pathobiology of various diseases - many of which may arise when inflammation or tissue injury becomes chronic - including fibrosis, atherosclerosis, arthritis and cancer, as well as diabetic nephropathy and retinopathy. Emerging studies indicate that targeting CCN protein expression or signalling pathways holds promise in the development of diagnostics and therapeutics for such diseases. This Review summarizes the biology of CCN proteins, their roles in various pathologies and their potential as therapeutic targets.

Indexed as

AnimalsCCN Intercellular Signaling ProteinsDisease Models, AnimalDrug Delivery SystemsExtracellular MatrixFibrosisHumansInflammation MediatorsNeoplasmsCCN Intercellular Signaling ProteinsInflammation Mediators

Identifiers

PMID22129992
PMCPMC3663145

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.